샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792918

세계의 B형 간염 치료 시장

Hepatitis B Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

B형 간염 치료 세계 시장은 2030년까지 54억 달러에 달할 전망

2024년에 47억 달러로 추정되는 B형 간염 치료 세계 시장은 2024년부터 2030년까지 CAGR 2.3%로 성장하여 2030년에는 54억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 급성형은 CAGR 1.7%를 기록하며 분석 기간 종료시에는 35억 달러에 달할 것으로 예측됩니다. 만성형 부문의 성장률은 분석 기간 동안 CAGR 3.5%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 4.4%로 성장 예측

미국의 B형 간염 치료 시장은 2024년에 13억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 10억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 0.9%와 1.7%로 예측됩니다. 유럽에서는 독일이 CAGR 1.2%로 성장할 것으로 예측됩니다.

세계의 B형 간염 치료 시장 - 주요 동향과 촉진요인 정리

B형 간염 치료는 기능적 치료와 장기 억제라는 새로운 시대로?

B형 간염 치료는 과학적 연구 발전, 치료 옵션의 개선, 바이러스의 복잡한 수명주기에 대한 깊은 이해로 인해 매우 중요한 변화의 시기를 맞이하고 있습니다. 기존에는 평생 항바이러스 요법으로 관리되어 온 B형 간염 치료는 간경변, 간세포암(HCC), 간부전의 위험을 줄이기 위해 바이러스 복제를 억제하는 데 중점을 두어 왔습니다. 엔테카비르, 테노포비르 디소프록실 푸마르산염(TDF), 테노포비르 알라페나미드(TAF)를 포함한 뉴클레오시드(t)이드 유사체 등의 1차 선택 약제는 지속적인 바이러스 억제에 효과적임이 입증되었으나, 완전한 완치에는 이르지 못했습니다. 그러나 새로운 연구 물결은 전문가들이 '기능적 치유'라고 부르는, 치료를 계속하지 않아도 B형 간염 표면 항원(HBsAg)이 사라지고 HBV DNA가 검출되지 않는 것을 정의하는 치유를 목표로 하고 있습니다. 캡시드 집합체 조절제, siRNA 억제제, 면역 체크포인트 조절제 등 임상시험 중인 신규 치료제 후보물질은 HBV의 생애주기의 다양한 단계와 숙주의 면역반응을 표적으로 삼아 치료의 한계를 뛰어넘어 치료의 한계를 뛰어넘으려 하고 있습니다. 치료용 백신과 T세포 활성화제를 포함한 면역치료 전략도 지속적인 바이러스 저장고에 대한 신체의 면역반응을 다시 불러일으키기 위한 목적으로 지지받고 있습니다. 항바이러스제와 면역조절제의 병용요법은 치료 후 지속적인 조절을 위한 진전으로 평가받고 있습니다. 이러한 임상시험 치료제가 임상시험을 통해 발전함에 따라 치료 패러다임은 평생 관리에서 기능적 완치를 목표로 하는 기간 제한 요법으로 전환되고 있으며, 이는 만성 B형 간염에 대한 전 세계 접근 방식에 획기적인 변화가 될 것입니다.

공중보건 인프라와 검진 인프라가 치료 접근과 진료를 촉진하고 있는가?

B형 간염에 대한 인식이 높아짐에 따라 공중보건 인프라와 전 세계 검진 노력이 개선되어 치료 접근성 및 치료율에 큰 영향을 미치고 있습니다. 만성 HBV 감염자 중 상당수는 간질환과 같은 합병증이 발생할 때까지 자신의 상태를 알지 못합니다. 이에 따라 각국은 국가 검진 프로그램을 확대하여 HBV 검사를 일상적인 임산부 검진, 헌혈자 검진, 일반 건강검진에 포함시키고 있습니다. 이러한 조치로 인해 조기 진단이 가능해졌고, 초기 환자는 항바이러스 치료에 잘 반응하기 때문에 이는 매우 중요합니다. 또한, 특히 아시아, 사하라 이남 아프리카 등 감염 위험이 높은 지역에서는 분산형 의료 모델과 지역 밀착형 아웃리치(outreach)가 도입되어 치료받지 못하는 사람들의 치료 접근성을 개선하고 있습니다. 또한, 많은 국가들이 WHO의 권고에 따라 치료 가이드라인을 개정하여 치료 시작의 장벽을 낮추고 항바이러스 치료의 자격 기준을 확대하고 있습니다. 또한, HBV 관리를 HIV/AIDS, 결핵, 임산부 건강 프로그램 등 보다 광범위한 보건 서비스에 통합하여 치료 제공을 간소화하고 환자 결과를 개선하고 있습니다. Gavi, 세계기금, UNITAID와 같은 세계 기부자 및 단체들은 약제비 지원 및 연구소 인프라 구축을 통해 중저소득 국가를 지원하고 있습니다. 한편, 디지털 헬스 플랫폼과 원격의료 서비스는 원격지 및 농촌 지역으로의 접근성을 확대하여 가상 진료, 원격 모니터링, 디지털 처방 관리 등을 가능하게 하고 있습니다. 이러한 노력으로 HBV 치료는 진단부터 치료 지속까지 이어지는 캐스케이드가 개선되어 전 세계 다양한 환자 집단의 요구에 맞는 치료 접근성, 경제성, 접근성 및 접근성이 향상되고 있습니다.

변화하는 환자 인구통계와 동반 질환은 치료 전략을 어떻게 재구성하고 있는가?

HIV, D형 간염, 당뇨병, 비알코올성 지방간질환(NAFLD) 등 동반 질환의 증가와 함께 환자 인구통계의 변화는 B형 간염 치료 전략에 복잡성을 더하고 있습니다. 노인의 만성질환 증가로 인해 임상의들은 HBV 치료를 시작할 때 약물 선택이 신장 및 뼈와 관련된 합병증을 악화시키지 않도록 보다 종합적인 접근 방식을 취해야 합니다. 이는 특히 고령자나 신장 기저질환이 있는 환자들에게 해당되며, 테노포비르 알라페나미드(TAF)는 안전성 프로파일이 개선되어 TDF보다 선호되는 경우가 많습니다. HIV와의 동시 감염은 약물-약물 상호작용을 피하고 두 바이러스를 확실히 억제하기 위해 치료 요법을 조화시켜야 하기 때문에 또 다른 임상적 과제를 제시합니다. D형 간염 바이러스(HDV)에 중복 감염된 환자(급속한 질병 진행 위험이 높은 그룹)의 경우, 이중 감염을 효과적으로 관리하기 위해 브레비티드와 같은 새로운 침입 억제제의 사용을 포함한 특수한 항바이러스 전략이 검토되고 있습니다. 이와 함께 대사증후군 및 비만과 관련된 간 손상이 전 세계적으로 증가함에 따라 HBV 환자의 간질환 진행이 더 이상 바이러스 복제만으로 인한 것이 아니기 때문에 치료 시기와 모니터링 프로토콜에 영향을 미치고 있습니다. 섬유화 점수, 간 효소 동향, 대사 지표를 통합한 새로운 알고리즘은 의료진이 위험을 계층화하고 치료 계획을 개별화할 수 있도록 돕고 있습니다. 또한, 환자의 복약 순응도와 삶의 질에 대한 고려가 치료 설계의 중심이 되고 있으며, 1일 1회 경구 요법 개발 및 지속형 주사제제 연구도 진행되고 있습니다. 이처럼 HBV 환자 프로파일의 다양화는 만성 간염 치료에서 맞춤형 의료를 재정의하고, 보다 섬세하고 환자 중심의 치료 경로를 요구하고 있습니다.

B형 간염 치료 부문의 성장을 가속화하는 시장 및 정책 촉진요인은 무엇인가?

B형 간염 치료제 시장의 성장은 역학 동향, 제약 혁신, 의료 정책의 진화, 환자 행동과 관련된 여러 가지 상호 연관된 힘에 의해 주도되고 있습니다. 전 세계적으로 2억 5천만 명 이상의 사람들이 만성 HBV에 감염되어 있으며, 대부분이 중저소득 국가에 거주하고 있습니다. 이 지역은 현재 WHO의 간염 퇴치 아젠다의 일환으로 치료 접근성을 적극적으로 확대하고 있습니다. 치료 가이드라인이 확대되어 초기 간질환이나 섬유화가 덜 진행된 환자도 치료 대상에 포함되면서 치료 대상자가 확대되고 항바이러스 요법에 대한 수요가 증가하고 있습니다. 기능적 치료, 순응도 개선, 장기 독성 감소 등을 목표로 개발 중인 차세대 치료제가 여러 가지 개발되고 있으며, 의약품의 기술 혁신이 시장의 모멘텀을 높이고 있습니다. 동시에 제네릭 의약품의 가용성이 높아짐에 따라, 특히 환자 부담이 큰 국가에서는 1차 선택 항바이러스제를 더 저렴하게 이용할 수 있게 되어 환자 수가 증가하고 공중보건 이니셔티브가 확대되고 있습니다. 각국 정부와 보건기관은 B형 간염 퇴치 계획에 착수하고 있으며, 치료 보조금 예산 배정, 집중 조달 전략, 필수 의약품 목록에 항바이러스제를 추가하는 등 시장 확대에 기여하고 있습니다. 환자의 행동도 변화하고 있으며, 건강 인식의 증가, 디지털 참여, 질병의 비체질화로 인해 검사 및 조기 개입을 원하는 사람들이 증가하고 있습니다. 한편, 제약사, NGO, 보건부 간의 파트너십은 라스트 마일 배송을 개선하기 위해 지역 치료 허브와 공급망 네트워크를 구축하는 데 도움을 주고 있습니다. 모바일 기반 순응도 도구, 원격 모니터링 플랫폼, AI를 활용한 임상적 판단 지원 시스템 등 디지털 헬스 기술의 도입은 환자 유지율과 치료의 질을 향상시키고 있습니다. 이러한 복합적인 요인들이 B형 간염 치료제 시장을 발전시키고 있으며, 전 세계가 가장 널리 퍼진 감염병을 퇴치하는 데 다가서면서 장기적으로 강력한 성장이 예상됩니다.

부문

유형(급성형, 만성형), 치료(면역 조정약치료, 항바이러스제 치료, 백신 치료, 수술 치료), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업 사례

  • AbbVie Inc.
  • Alnylam Pharmaceuticals
  • Altimmune Inc.
  • Antios Therapeutics
  • Arbutus Biopharma Corporation
  • Assembly Biosciences
  • Bristol-Myers Squibb
  • Dicerna Pharmaceuticals
  • Enanta Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • LG Chem
  • MYR Pharmaceuticals GmbH
  • Replicor Inc.
  • Roche Holding AG
  • Sanofi
  • VBI Vaccines Inc.
  • Vir Biotechnology, Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.25

Global Hepatitis B Treatment Market to Reach US$5.4 Billion by 2030

The global market for Hepatitis B Treatment estimated at US$4.7 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2024-2030. Acute Type, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Chronic Type segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 4.4% CAGR

The Hepatitis B Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Hepatitis B Treatment Market - Key Trends & Drivers Summarized

Is the Treatment of Hepatitis B Entering a New Era of Functional Cure and Long-Term Suppression?

The treatment of Hepatitis B is undergoing a pivotal transformation, driven by advancing scientific research, improved therapeutic options, and a deeper understanding of the virus's complex life cycle. Traditionally managed through lifelong antiviral therapy, Hepatitis B treatment has focused on suppressing viral replication to reduce the risk of liver cirrhosis, hepatocellular carcinoma (HCC), and liver failure. First-line therapies such as nucleos(t)ide analogues-including entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)-have proven effective in achieving sustained viral suppression, but fall short of offering a complete cure. However, a new wave of research is aiming for what experts call a “functional cure,” defined by the loss of hepatitis B surface antigen (HBsAg) and undetectable HBV DNA without continued treatment. Novel therapeutic candidates in clinical trials-such as capsid assembly modulators, siRNA inhibitors, and immune checkpoint modulators-are targeting different phases of the HBV life cycle and the host’s immune response to push the boundaries of treatment beyond suppression. Immunotherapeutic strategies including therapeutic vaccines and T-cell activators are also gaining traction, aiming to reawaken the body’s immune response against persistent viral reservoirs. Combination therapies involving antivirals plus immune modulators are being evaluated as a path forward toward sustained off-treatment control. As these investigational therapies progress through clinical trials, the treatment paradigm is shifting from lifelong management to time-limited regimens aimed at achieving functional cure, which would represent a landmark change in the global approach to chronic Hepatitis B.

Is Public Health Infrastructure and Screening Enhancing Treatment Accessibility and Uptake?

As awareness around Hepatitis B grows, improvements in public health infrastructure and global screening efforts are significantly influencing treatment accessibility and uptake. One of the biggest barriers historically has been the lack of diagnosis-most people with chronic HBV remain unaware of their status until complications like liver disease arise. In response, countries are scaling up national screening programs, integrating HBV testing into routine prenatal care, blood donor screening, and general health checkups. These measures are enabling earlier diagnosis, which is crucial since early-stage patients respond more favorably to antiviral therapy. Furthermore, decentralized healthcare models and community-based outreach are being deployed in high-burden regions-especially in Asia and sub-Saharan Africa-to improve access to treatment for underserved populations. Many nations are also revising their treatment guidelines in line with WHO recommendations, reducing the barriers to initiating therapy and expanding eligibility criteria for antiviral treatment. Additionally, integration of HBV management into broader health services such as HIV/AIDS, tuberculosis, and maternal health programs is streamlining care delivery and improving patient outcomes. Global donors and organizations like Gavi, the Global Fund, and UNITAID are supporting low- and middle-income countries by subsidizing medication costs and building lab infrastructure. Meanwhile, digital health platforms and telemedicine services are increasing outreach in remote and rural areas, enabling virtual consultations, remote monitoring, and digital prescription management. Together, these efforts are improving HBV treatment cascade-from diagnosis to retention in care-by making therapy more accessible, affordable, and aligned with the unique needs of diverse patient populations around the world.

How Are Evolving Patient Demographics and Comorbidities Reshaping Treatment Strategies?

Shifting patient demographics, along with an increase in comorbidities such as HIV, hepatitis D, diabetes, and non-alcoholic fatty liver disease (NAFLD), are adding layers of complexity to Hepatitis B treatment strategies. The rise in chronic conditions among aging populations is prompting clinicians to take a more holistic approach when initiating HBV therapy, ensuring that drug choices do not exacerbate renal or bone-related complications. This is especially relevant for older adults or those with underlying kidney disease, where tenofovir alafenamide (TAF) is often preferred over TDF due to its improved safety profile. Co-infection with HIV presents another clinical challenge, as treatment regimens must be harmonized to avoid drug-drug interactions and ensure suppression of both viruses. For patients with hepatitis D virus (HDV) co-infection-a group at higher risk of rapid disease progression-specialized antiviral strategies, including the use of novel entry inhibitors like bulevirtide, are being explored to manage dual infections effectively. In parallel, the global rise of metabolic syndromes and obesity-related liver disorders is influencing treatment timing and monitoring protocols, as liver disease progression in HBV patients is no longer driven solely by viral replication. New algorithms that integrate fibrosis scores, liver enzyme trends, and metabolic indicators are helping providers stratify risk and personalize treatment plans. Furthermore, patient adherence and quality of life considerations are becoming central to therapy design, prompting the development of once-daily oral regimens and the investigation of long-acting injectable formulations. The diversification of HBV patient profiles is thus redefining what personalized medicine looks like in the context of chronic hepatitis care, necessitating more nuanced and patient-centric treatment pathways.

What Market and Policy Drivers Are Accelerating Growth in the Hepatitis B Treatment Segment?

The growth in the Hepatitis B treatment market is driven by several interconnected forces tied to epidemiological trends, pharmaceutical innovation, health policy evolution, and patient behavior. Globally, over 250 million people live with chronic HBV, and the majority reside in low- and middle-income countries-regions now actively scaling up treatment access as part of WHO’s hepatitis elimination agenda. The expansion of treatment guidelines to include patients with earlier-stage liver disease and less advanced fibrosis is widening the eligible treatment population, increasing demand for antiviral therapies. Pharmaceutical innovation continues to drive market momentum, with several next-generation therapies under development aiming to deliver functional cure, improve adherence, or reduce long-term toxicity. Simultaneously, increasing generic drug availability is making first-line antivirals more affordable, especially in high-burden countries, leading to higher patient volumes and expanded public health initiatives. Governments and health agencies are launching hepatitis B elimination plans that include budget allocations for treatment subsidies, centralized procurement strategies, and inclusion of antivirals in essential drug lists-steps that are all contributing to market expansion. Patient behavior is also shifting, with more individuals seeking testing and early intervention due to rising health awareness, digital engagement, and destigmatization of the disease. Meanwhile, partnerships between pharmaceutical companies, NGOs, and health ministries are helping to establish regional treatment hubs and supply chain networks to improve last-mile delivery. The adoption of digital health technologies-such as mobile-based adherence tools, remote monitoring platforms, and AI-powered clinical decision support systems-is enhancing patient retention and care quality. These combined factors are propelling the Hepatitis B treatment market forward, with strong long-term growth anticipated as the world moves closer to eradicating one of the most prevalent infectious diseases.

SCOPE OF STUDY:

The report analyzes the Hepatitis B Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Type, Chronic Type); Treatment (Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment, Surgery Treatment); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Alnylam Pharmaceuticals
  • Altimmune Inc.
  • Antios Therapeutics
  • Arbutus Biopharma Corporation
  • Assembly Biosciences
  • Bristol-Myers Squibb
  • Dicerna Pharmaceuticals
  • Enanta Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • LG Chem
  • MYR Pharmaceuticals GmbH
  • Replicor Inc.
  • Roche Holding AG
  • Sanofi
  • VBI Vaccines Inc.
  • Vir Biotechnology, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hepatitis B Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Global Disease Burden Throws the Spotlight on Expanding Access to Hepatitis B Treatment
    • Increased Government and WHO-Led Elimination Goals Propel Growth in Treatment Uptake
    • Advancements in Antiviral Therapies Strengthen Business Case for Long-Term Viral Suppression
    • Rising Screening and Diagnosis Rates Expand the Addressable Market for Hepatitis B Treatment
    • Development of Finite-Duration Therapies Spurs Innovation in Functional Cure Approaches
    • Growing Pipeline of Novel Nucleos(t)ide Analogs and Immunotherapies Drives R&D Investment
    • Increased Use of Combination Regimens Generates Demand for Optimized Treatment Protocols
    • Improved Access to Generic Medications Sustains Growth in Low- and Middle-Income Countries
    • Integration of Hepatitis B Care into Broader Public Health Programs Expands Treatment Reach
    • Rising Co-Infection Rates with HIV and Hepatitis D Spur Development of Broader-Spectrum Therapeutics
    • Digital Health Tools and Adherence Monitoring Platforms Drive Improved Patient Outcomes
    • Awareness Campaigns and Early Intervention Strategies Propel Patient Engagement and Treatment Initiation
    • Healthcare Infrastructure Improvements in Emerging Markets Strengthen Market Penetration
    • Persistent Stigma and Asymptomatic Nature of Disease Pose Challenges to Treatment Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis B Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immune Modulator Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immune Modulator Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immune Modulator Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antiviral Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Vaccines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Hepatitis B Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Hepatitis B Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Hepatitis B Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Hepatitis B Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Hepatitis B Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Hepatitis B Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Hepatitis B Treatment by Type - Acute Type and Chronic Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Hepatitis B Treatment by Type - Acute Type and Chronic Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Hepatitis B Treatment by Type - Percentage Breakdown of Value Sales for Acute Type and Chronic Type for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Hepatitis B Treatment by Treatment - Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Hepatitis B Treatment by Treatment - Percentage Breakdown of Value Sales for Immune Modulator Drugs Treatment, Antiviral Drugs Treatment, Vaccines Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Hepatitis B Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Hepatitis B Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제